Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine

Neuropsychopharmacology

Volumn 32, Issue 3, 2007, Pages 658-664

  Kaneko, Yujiro ^a   Kashiwa, Atsushi ^a   Ito, Takashi ^a   Ishii, Sumikazu ^a   Umino, Asami ^a   Nishikawa, Toru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Behavioral sensitization; Fluoxetine; Methamphetamine; Methamphetamine psychosis; Paroxetine; Schizophrenia

Indexed keywords

FLUOXETINE; METHAMPHETAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DISEASE MODEL; DRUG DEPENDENCE TREATMENT; HALLUCINATION; MALE; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PARANOIA; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHOSIS; RELAPSE; REPEATED DRUG DOSE; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOXETINE; HEAD MOVEMENTS; LOCOMOTION; METHAMPHETAMINE; MICE; PAROXETINE; PSYCHOSES, SUBSTANCE-INDUCED; RECURRENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 33847013753     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301111     Document Type: Article

References (46)

1. 1A receptor modulates the effects of cocaine on extracellular serotonin and dopamine levels in the nucleus accumbens. Eur J Pharmacol 508: 123-130.
2. Antelman SM, Eichler AJ, Black CA, Kocan D (1980). Interchangeability of stress and amphetamine in sensitization. Science 207: 329-331.
3. 2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 20: 3073-3084.
4. Bronsert MR, Mead AN, Hen R, Rocha BA (2001). Amphetamine-induced locomotor activation in 5-HT(1B) knockout mice: effects of injection route on acute and sensitized responses. Behav Pharmacol 12: 549-555.
5. Carroll ME, Lac ST, Asencio M, Kragh R (1990). Intravenous cocaine self-administration in rats is reduced by dietary L-tryptophan. Psychopharmacology (Berlin) 100: 293-300.
6. 2 receptor antagonists given in the acute withdrawal from daily cocaine injections can reverse established sensitization. Eur J Pharmacol 453: 255-263.
7. Davidson C, Lee TH, Xiong Z, Ellinwood EH (2002b). Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. Neuropsychopharmacology 27: 542-553.
8. De Deurwaerdere P, Moison D, Navailles S, Porras G, Spampinato U (2005). Regionally and functionally distinct serotonin3 receptors control in vivo dopamine outflow in the rat nucleus accumbens. J Neurochem 94: 140-149.
9. Duman RS, Nakagawa S, Malberg J (2001). Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 25: 836-844.
10. Ellinwood Jr EH, Sudilovsky A, Nelson LM (1973). Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry 130: 1088-1093.
11. Esposito E (2006). Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 7: 177-185.
12. Felton TM, Kang TB, Hjorth S, Auerbach SB (2003). Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 367: 297-305.
13. Goeldner FO, Pigatto G, Ribeiro AF, Machado HB, Boerngen-Lacerda R (2005). Influence of fluoxetine and paroxetine in behavioral sensitization induced by ethanol in mice. Pharmacol Biochem Behav 82: 388-396.
14. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y (2003). Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 23: 742-747.
15. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM et al (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30: 345-354.
16. Hiemke C, Hartter S (2000). Pharmacokinetics of selective 5-HT reuptake inhibitors. Pharmacol Ther 85: 11-28.
17. 3 receptor antagonist, administered during withdrawal from intermittent and continuous cocaine. Psychopharmacology (Berlin) 135: 263-269.
18. King GR, Xiong Z, Douglass S, Ellinwood EH (2000). Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT(3) receptor antagonist. Eur J Pharmacol 394: 97-101.
19. Kodama M, Fujioka T, Duman RS (2004). Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56: 570-580.
20. Le Foll B, Diaz J, Sokoloff P (2005). A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. NeuroReport 16: 175-178.
21. Li Y, White FJ, Wolf ME (2000). Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Psychopharmacology 151: 175-183.
22. Lyness WH (1983). Effect of L-tryptophan pretreatment on d-amphetamine self administration. Subst Alcohol Actions Misuse 4: 305-312.
23. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104-9110.
24. Malberg JE, Duman RS (2003). Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 28: 1562-1571.
25. Masuo Y, Noguchi J, Morita S, Matsumoto Y (1995). Effects of intracerebroventricular administration of pituitary adenylate cyclase-activating polypeptide (PACAP) on the motor activity and reserpine-induced hypothermia in murines. Brain Res 700: 219-226.
26. Meredith GE, Callen S, Scheuer DA (2002). Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 949: 218-227.
27. Nishikawa T, Mataga N, Takashima M, Toru M (1983). Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur J Pharmacol 88: 195-203.
28. Parsons LH, Koob GF, Weiss F (1995). 5-HT dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 274: 1182-1191.
29. Poyurovsky M, Isakov V, Hromnikov S, Modai I, Rauchberger B, Schneidman M et al (1999). Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol 14: 95-100.
30. Richardson NR, Roberts DC (1991). Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci 49: 833-840.
31. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396: 157-198.
32. Rocha BA, Scearce-Levie K, Lucas JJ, Hiroi N, Castanon N, Crabbe JC et al (1998). Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature 393: 175-178.
33. Segal DS, Janowsky DS (1978). Psychostimulant-induced behavioral effects: possible models of schizophrenia. In: Lipton MA, DiMascio A, Killam KF (eds). Psychopharmacology: A Generation of Progress. Raven Press: New York. pp 1113-1123.
34. Shen H, Hagino Y, Kobayashi H, Numachi Y, Yamamoto H, Yamamoto T et al (2003). Methamphetamine sensitization in dopamine (DAT) and/or 5-HT (SERT) transporter knockout mice. The Society for Neuroscience 33rd Annual Meeting, New Orleans, USA [2003/11/8-14].
35. Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ (2000). Subchronic fluoxetine treatment induces a transient potentiation of amphetamine-induced hyperlocomotion: possible pharmacokinetic interaction. Behav Pharmacol 11: 109-116.
36. Silver H, Shmugliakov N (1998). Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 18: 208-211.
37. Silver H (2004). Selective 5-HT re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 5: 2053-2058.
38. Snyder SH (1973). Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines. Am J Psychiatry 130: 61-67.
39. Sodhi MS, Sanders-Bush E (2004). 5-HT and brain development. Int Rev Neurobiol 59: 111-174.
40. Takamatsu Y, Yamamoto H, Hagino Y, Markou A, Ikeda K (2005). Fluoxetine as a potential pharmacotherapy for methamphetamine dependence. Ann NY Acad Sci (in press).
41. 1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res 52: 185-194.
42. Ujike H, Sato M (2004). Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci 1025: 279-287.
43. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berlin) 151: 99-120.
44. Yamaguchi M, Suzuki T, Seki T, Namba T, Juan R, Arai H et al (2004). Repetitive cocaine administration decreases neurogenesis in adult rat hippocampus. Ann NY Acad Sci 1025: 351-362.
45. Yan QS, Yan SE (2001). Activation of 5-HT(1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur J Pharmacol 418: 55-64.
46. Yan QS, Zheng SZ, Yan SE (2004). Involvement of 5-HT1B receptors within the ventral tegmental area in regulation of mesolimbic dopaminergic neuronal activity via GABA mechanisms: a study with dual-probe microdialysis. Brain Res 1021: 82-91.